Trial Profile
A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2021
Price :
$35
*
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Acronyms Open PRIDE-HD
- Sponsors Teva Branded Pharmaceutical Products R&D
- 17 Aug 2018 Status changed to discontinued as this study served its purpose in providing considerable safety data. The decision to terminate the studies was not based on any new or emerging safety concern.
- 12 Dec 2017 Planned End Date changed from 27 Apr 2023 to 31 Jan 2018.
- 12 Dec 2017 Planned primary completion date changed from 30 Mar 2023 to 29 Dec 2017.